Controlled release of a GnRH agonist from a polyhydroxybutyric acid implant: reversible suppression of the menstrual cycle in the macaque.
The use of polyhydroxybutyric acid as a matrix for delivery of the GnRH agonist buserelin was studied in adult stumptailed macaques with regular menstrual cycles. This material contained 5.0 mg buserelin in a disk of 0.6 cm diameter and 0.15 cm thickness. The effects on pituitary-ovarian function were examined and buserelin release profiles from 30,000 and 150,000 molecular weight polyhydroxybutyric acid matrices were compared. In an attempt to reduce the high initial release rate of buserelin from these disks, and to prolong the effective period of release, implants of 30,000 molecular weight were coated with cyanoacrylate. The implants were removed after 28, 35 or 42 days for the 30,000, the 150,000 and the coated implants, respectively. The urinary excretion profile for the agonist revealed a high initial release of buserelin from these implants followed by a rapid decline. The coated disks released significantly less (p less than 0.05) buserelin over the first 3 days than did either of the uncoated implants, but maintained release of the agonist over a longer period. Inhibition of ovulation and suppression of estradiol secretion lasted for the duration of treatment in 3 of 5 macaques receiving the 30,000 implant, and in 5 of 5 receiving the 150,000 or the coated implant. In 3 macaques in whom the coated implant was left in situ, ovulation was suppressed for 104 +/- 3.7 days. These results demonstrate that a polyhydroxybutyric acid matrix can be used as a depot formulation for a GnRH agonist and that improved control of release of the agonist can be achieved by coating such implants with cyanoacrylate. This approach may be useful in experimental and clinical situations and may be applicable for delivery of other peptide hormones.
Fraser
H M
HM
MRC Reproductive Biology Unit, Centre for Reproductive Biology, Edinburgh, UK.
Sandow
J
J
Seidel
H R
HR
Lunn
S F
SF
D000818:Animals; D002064:Buserelin / Q000008:administration & dosage* / Q000652:urine; D003692:Delayed-Action Preparations; D004343:Drug Implants; D005260:Female; D006885:Hydroxybutyrates / Q000008:administration & dosage*; D008251:Macaca; D008598:Menstruation / Q000187:drug effects*; D010053:Ovary / Q000187:drug effects; D010902:Pituitary Gland / Q000187:drug effects; D011091:Polyesters / Q000008:administration & dosage*; D000094122:Polyhydroxybutyrates
D002064:Buserelin; D003692:Delayed-Action Preparations; D004343:Drug Implants; D006885:Hydroxybutyrates; D011091:Polyesters; C003182:poly-beta-hydroxybutyrate; D000094122:Polyhydroxybutyrates